Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
Cord blood (CB) is a promising alternative source for patients without HLA-matched donors. However, delayed platelet recovery after CB transplantation (CBT) is yet to be solved. We focused on megakaryopoiesis after CBT through megakaryocytic progenitors (MKP), which is novel differentiation pathway. We aimed to clarify the mechanism which intra-bone injection of CB and thrombopoietin receptor agonist (TPO-RA) promotes platelet recovery via MKP pathway. We found that the number of MKP was increased after intra-bone injection of CB using mouse models. TPO, which is indispensable for differentiation of MKP, was expressed on stromal cells in the bone marrow. Analysis of the nation-wide database of hematopoietic stem-cell transplantation revealed that the survival of patients who achieved platelet recovery after CBT was comparable to that after bone marrow transplantation. Based on these findings, we are also conducting a clinical trial of TPO-RA administration in the early phase after CBT.
|